Cycle length: Weekly OR every two weeks. | |||
Drug | Dose and route | Administration | Given on days |
Cetuximab (loading dose)[1] | 400 mg/m2 IV | The appropriate dose should be withdrawn from the vials (supplied in a concentration of 2 mg/mL) and aseptically transferred into an empty sterile IV bag without further dilution. The initial dose should be infused over 120 minutes.*¶ | Day 1 |
Cetuximab | 250 mg/m2 IV | If day 1 is tolerated, subsequent doses may be administered over 60 minutes. | Weekly, beginning day 8Δ |
OR | |||
Cetuximab (loading dose and subsequent)Δ[2] | 500 mg/m2 IV | The appropriate dose should be withdrawn from the vials (supplied in a concentration of 2 mg/mL) and aseptically transferred into an empty sterile IV bag without further dilution.*¶ When administered every 2 weeks, all doses should be infused over 120 minutes. | Every 2 weeks |
Pretreatment considerations: | |||
Emesis risk |
| ||
Prophylaxis for infusion reactions |
| ||
Monitoring parameters: | |||
| |||
| |||
Suggested dose modifications for toxicity: | |||
Dermatologic toxicity |
| ||
If there is a change in body weight of at least 10%, doses should be recalculated. |
FDA: US Food and Drug Administration; IgE: immunoglobulin E; IV: intravenous.
* Cetuximab should be administered with an infusion or syringe pump, using a low protein-binding 0.22 micron in line filter. Do not shake or dilute. Flush line with normal saline.
¶ A slower infusion rate should be considered in areas with a high incidence of infusion reactions (such as the southeast United States). Refer to UpToDate topics on infusion reactions to therapeutic monoclonal antibodies used in cancer therapy.
Δ Results from a nonrandomized phase II trial[3] and a multicenter retrospective analysis[4] suggest that cetuximab at a dose of 500 mg/m2 initially followed by 500 mg/m2 every 2 weeks results in similar plasma concentrations and single-agent activity as does weekly dosing. This regimen is now approved by the FDA.[2]
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟